Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Layton

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Drug Safety|July 29, 2006
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in EnglandDeborah Layton, Vanessa Marshall, Andrew Boshier, et al.
The International Journal of Pharmacy Practice|October 10, 2017
Safety of Atrovent<sup>®</sup> CFC-free inhaler: respiratory events reported from an observational cohort study in EnglandVicki Osborne, Deborah Layton, Carole Fogg, et al.
Cancers|January 25, 2025
Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE DatabaseStefanie Ho Yi Chan, Raymond W Fitzpatrick, Deborah Layton, et al.
Drug Safety|May 10, 2013
Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in EnglandYvonne Buggy, Victoria Cornelius, Carole Fogg, et al.
Drug Safety|September 15, 2006
Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in EnglandDeborah Layton, Lynda Wilton, Andrew Boshier, et al.
Pharmacoepidemiology and Drug Safety|December 26, 2025
Incidence of Diabetic Ketoacidosis in Dapagliflozin-Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database StudyReiko Tamura, Hyosung Kim, Yuko Takumi, et al.
Drug Safety|January 26, 2008
Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The NetherlandsDeborah Layton, Patrick C Souverein, Eibert R Heerdink, et al.
Pharmacoepidemiology and Drug Safety|September 30, 2008
Prescriber adoption of newly approved selective COX-2 inhibitorsDeborah Layton, Patrick C Souverein, Eibert R Heerdink, et al.
Drug Safety|April 12, 2022
Correction to: A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION ProjectLeonardo Roque Pereira, Carlos E Durán, Deborah Layton, et al.
BMJ Open|October 19, 2017
Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohortAbigail L Coughtrie, Elijah R Behr, Deborah Layton, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Drug Safety|July 29, 2006
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in EnglandDeborah Layton, Vanessa Marshall, Andrew Boshier, et al.
The International Journal of Pharmacy Practice|October 10, 2017
Safety of Atrovent<sup>®</sup> CFC-free inhaler: respiratory events reported from an observational cohort study in EnglandVicki Osborne, Deborah Layton, Carole Fogg, et al.
Cancers|January 25, 2025
Cancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE DatabaseStefanie Ho Yi Chan, Raymond W Fitzpatrick, Deborah Layton, et al.
Drug Safety|May 10, 2013
Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in EnglandYvonne Buggy, Victoria Cornelius, Carole Fogg, et al.
Drug Safety|September 15, 2006
Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in EnglandDeborah Layton, Lynda Wilton, Andrew Boshier, et al.
Pharmacoepidemiology and Drug Safety|December 26, 2025
Incidence of Diabetic Ketoacidosis in Dapagliflozin-Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database StudyReiko Tamura, Hyosung Kim, Yuko Takumi, et al.
Drug Safety|January 26, 2008
Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The NetherlandsDeborah Layton, Patrick C Souverein, Eibert R Heerdink, et al.
Pharmacoepidemiology and Drug Safety|September 30, 2008
Prescriber adoption of newly approved selective COX-2 inhibitorsDeborah Layton, Patrick C Souverein, Eibert R Heerdink, et al.
Drug Safety|April 12, 2022
Correction to: A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION ProjectLeonardo Roque Pereira, Carlos E Durán, Deborah Layton, et al.
BMJ Open|October 19, 2017
Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohortAbigail L Coughtrie, Elijah R Behr, Deborah Layton, et al.
Pageof 6